An experimental obesity drug from Novo Nordisk resulted in 15.7% weight loss after 68 weeks of treatment — falling short of the company’s expectations of 25% weight loss.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
Novo Nordisk drug yields 15.7% weight loss in phase 3 trial
